| סיכום: | Chikungunya virus (CHIKV) is a reemerging mosquito-borne virus that causes swift outbreaks. Major concerns are the persistent and disabling polyarthralgia in infected individuals.
Here we present the results from a first-in-human trial of the candidate simian adenovirus
vectored vaccine ChAdOx1 Chik, expressing the CHIKV full-length structural polyprotein
(Capsid, E3, E2, 6k and E1). 24 adult healthy volunteers aged 18–50 years, were recruited in a
dose escalation, open-label, nonrandomized and uncontrolled phase 1 trial (registry
NCT03590392). Participants received a single intramuscular injection of ChAdOx1 Chik at
one of the three preestablished dosages and were followed-up for 6 months. The primary
objective was to assess safety and tolerability of ChAdOx1 Chik. The secondary objective was
to assess the humoral and cellular immunogenicity. ChAdOx1 Chik was safe at all doses
tested with no serious adverse reactions reported. The vast majority of solicited adverse
events were mild or moderate, and self-limiting in nature. A single dose induced IgG and Tcell responses against the CHIKV structural antigens. Broadly neutralizing antibodies against
the four CHIKV lineages were found in all participants and as early as 2 weeks after vaccination. In summary, ChAdOx1 Chik showed excellent safety, tolerability and 100% PRNT50
seroconversion after a single dose.
|
|---|